Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:10286 |
Name | prostate carcinoma |
Definition | A prostate cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RB1 mut TP53 mut | R547 | prostate carcinoma | sensitive | detail... |
PTEN loss | SAR260301 | prostate carcinoma | decreased response | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01385228 | Phase I | Docetaxel + Pazopanib + Pegfilgrastim | Pazopanib, Docetaxel, Prednisone Prostate | Completed | USA | 0 |
NCT01391143 | Phase I | MGA271 | Safety Study of MGA271 in Refractory Cancer | Completed | USA | 0 |
NCT01561482 | Phase II | Metformin + Simvastatin | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | Withdrawn | USA | 0 |
NCT02113657 | Phase II | Ipilimumab | T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer | Completed | USA | 0 |
NCT02234115 | Phase III | Leuprolide | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma | Completed | USA | SVK | POL | LTU | DEU | CZE | AUT | 1 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |
NCT02552394 | Phase I | J591 | J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts | Completed | USA | 0 |
NCT02565901 | Phase Ib/II | Carboplatin + Docetaxel + Sirolimus | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Completed | USA | NLD | ITA | FRA | ESP | CAN | AUS | 2 |
NCT02952534 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) | Completed | USA | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 0 |
NCT02975934 | Phase III | Rucaparib Docetaxel Enzalutamide Abiraterone | A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | Active, not recruiting | USA | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 0 |
NCT03261999 | Phase III | Leuprolide | Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer | Completed | USA | SVK | LTU | CZE | 1 |
NCT03263650 | Phase II | Cabazitaxel + Carboplatin Olaparib | Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | Active, not recruiting | USA | 0 |
NCT03336983 | Phase II | Enzalutamide + Triptorelin Enzalutamide + Triptorelin + Zoledronic acid | Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients | Completed | ITA | 0 |
NCT03837353 | Phase Ib/II | DKN-01 DKN-01 + Docetaxel | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | Terminated | USA | 0 |
NCT04179396 | Phase I | Enzalutamide + Rucaparib Abiraterone + Rucaparib | Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) (RAMP) | Completed | USA | 0 |
NCT04388852 | Phase I | DS-3201b + Ipilimumab | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | Recruiting | USA | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04592237 | Phase II | Niraparib Cabazitaxel + Carboplatin + Cetrelimab Cetrelimab + Niraparib | Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04631744 | Phase II | Cabozantinib | Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Recruiting | USA | 0 |
NCT04709276 | Phase II | Cabazitaxel + Carboplatin + Ipilimumab + Nivolumab | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) | Recruiting | USA | 0 |
NCT04947254 | Phase II | Apalutamide Abiraterone + Apalutamide + Niraparib + Prednisone | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | Recruiting | USA | 0 |
NCT05169684 | Phase II | BMS-986218 + Docetaxel Docetaxel BMS-986218 + Nivolumab BMS-986218 + Docetaxel + Nivolumab | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | Completed | USA | NLD | ITA | GRC | GBR | FRA | CAN | ARG | 0 |
NCT05265988 | Phase II | Cabozantinib | Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib (MERIDIAN) | Completed | ITA | 0 |
NCT05655715 | Phase II | Ipilimumab + Nivolumab | Checkpoint Inhibitors and SBRT for mCRPC (CheckPRO) | Completed | DNK | 0 |
NCT06457919 | Phase Ib/II | Abiraterone + Enzalutamide + Tinengotinib Abiraterone + Prednisone + Tinengotinib | A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | Recruiting | USA | 0 |
NCT06576037 | Phase I | CBP-1019 + Enzalutamide CBP-1019 + Pembrolizumab Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | Not yet recruiting | USA | 0 |